SCHEMBL5185241

SCHEMBL5185241

COC(=O)C(c1cccs1)N(CC(=O)O)C(=O)OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.39
LMNA P02545 3/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
THRB P10828 1/20 0.39
KDM4E B2RXH2 2/20 0.37
ALOX5 P09917 1/20 0.37
TACR3 P29371 1/20 0.36
CYP3A4 P08684 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
GPX4 P36969 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
CYP1A2 P05177 1/20 0.35
MAPT P10636 1/20 0.35
YAP1 P46937 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4693729 0.91 LMNA (0.39) NPSR1LMNATP53POLBTHRB
SCHEMBL4138910 0.84 GSTO1 (0.36) NPSR1LMNATP53POLBTHRB
SCHEMBL4693070 0.77 GSTO1 (0.36) NPSR1LMNATP53POLBTHRB
SCHEMBL5252111 0.73 KMT2A (0.43) CYP2D6TSHRSMN1; SMN2HPGDNR1H2
SCHEMBL2821064 0.70 HPGD (0.45) KDM4EALOX5TACR3CYP3A4CYP2D6
SCHEMBL9000694 0.69 CES2 (0.56) KDM4EALOX5TACR3CYP3A4CYP2D6
SCHEMBL2370589 0.69 HPGD (0.55) NPSR1LMNATP53POLBTHRB
SCHEMBL8237520 0.69 HPGD (0.44) LMNATP53POLBKDM4EALOX5
SCHEMBL12895886 0.69 HPGD (0.55) NPSR1LMNATP53POLBTHRB
SCHEMBL667372 0.68 HPGD (0.41) NPSR1TP53KDM4EALOX5TACR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288549-B2 Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents AVENTIS PHARMA S.A. (FR) 2007-10-30 US disclosed
US-20050245505-A1 Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents ENTASIS THERAPEUTICS LIMITED (GB) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245505-A1 Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents FDPS, MRPL21, DHPS NPSR1 2649/4885LMNA 2806/4885TP53 4616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.